The mechanism of adjuvanticity of aluminium-containing formulas

Current Pharmaceutical Design

Volumn 18, Issue 16, 2012, Pages 2305-2313

  Fierens, Kaat ^a,b   Kool, Mirjam ^a,c  

^a GHENT UNIVERSITY   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvant; Aluminium hydroxide; Dendritic cell; NLRP3; Syk; Uric acid and dsDNA

Indexed keywords

ADJUVANT; ALUMINUM DERIVATIVE; ALUMINUM HYDROXIDE; ALUMINUM POTASSIUM SULFATE; CRYOPYRIN; DOUBLE STRANDED DNA; MIFAMURTIDE; PROTEIN KINASE SYK; URIC ACID; VACCINE;

CELL ACTIVATION; CELLULAR IMMUNITY; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; DRUG FORMULATION; DRUG MECHANISM; GRANULOMA; HUMAN; IMMUNOSTIMULATION; INJECTION SITE REACTION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM; ANIMALS; HUMANS;

EID: 84860170373     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212800166004     Document Type: Review

References (119)

1. Brewer JM (2006). (How) do aluminium adjuvants work? Immunol Lett 102 (1): 10-15.
2. Jenner E. An inquiry into the causes and effects of variolae vaccinae, Or Cowpox. London, Sampson Low 1798.
3. Lambrecht BN, Kool M, Willart MA, Hammad H (2009). Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 21 (1):23-29.
4. Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O'Hagan DT, De Gregorio E, Seubert A, Wack A (2011). Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29 (9): 1812-1823.
5. Aimanianda V, Haensler J, Lacroix-Desmazes S, Kaveri SV, Bayry J (2009). Novel cellular and molecular mechanisms of induction of immune responses by aluminumadjuvants. Trends Pharmacol Sci 30 (6): 287-295.
6. Fraser CK, Diener KR, Brown MP, Hayball JD (2007). Improving vaccines by incorporating immunological coadjuvants. Expert Rev Vaccines 6 (4): 559-578.
7. Guy B (2007). The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007 5 (7): 505-517.
8. Pashine A, Valiante NM, Ulmer JB (2005). Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11(4): 63-68.
9. Gavin AL, Hoebe K, Duong B, Ota T, Martin C, Beutler B, Nemazee D (2006). Adjuvant-enhanced antibody responses in the absence of toll-like receptor signalling. Science 314 (5807): 1936-1938.
10. Nemazee D, Gavin A, Hoebe K, Beutler B (2006). Immunology: Toll-like receptors and antibody responses. Nature 441 (7091): discussion E4.
11. Fearon DT, Locksley RM (1996). The instructive role of innate immunity in the acquired immune response. Science 272 (5258): 50-53.
12. Medzhitov R, Janeway CA Jr (1997). Innate immunity: the virtues of a nonclonal system of recognition. Cell 91 (3): 295-298.
13. Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, O'Hagan D, Rappuoli R, De Gregorio E (2008). Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 105 (30): 10501-10506.
14. Takeda K, Akira S (2005). Toll-like receptors in innate immunity. Int Immunol 17 (1):1-14.
15. Beutler B, Jiang Z, Georgel P, Crozat K, Croker B, Rutschmann S, Du X, Hoebe K (2006). Genetic analysis of host resistance: Tolllike receptor signaling and immunity at large. Annu Rev Immunol 24: 353-389.
16. Hunter RL (2002). Overview of vaccine adjuvants: present and future. Vaccine 20 (3): S7-12.
17. Jordan MB, Mills DM, Kappler J, Marrack P, Cambier JC (2004). Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304(5678): 1808-1810.
18. Wang HB, Weller PF (2008). Pivotal advance: eosinophils mediate early alum adjuvant-elicited B cell priming and IgM production. J Leukoc Biol 83 (4): 817-821.
19. Naim JO, van Oss CJ, Wu W, Giese RF, Nickerson PA (1997). Mechanisms of adjuvancy: I--Metal oxides as adjuvants. Vaccine 15 (11): 1183-1193.
20. Wijburg OL, van den Dobbelsteen GP, Vadolas J, Sanders A, Strugnell RA, van Rooijen N (1998). The role of macrophages in the induction and regulation of immunity elicited by exogenous antigens. Eur J Immunol 28 (2): 479-487.
21. Bomford R (1980). The comparative selectivity of adjuvants for humoral and cell-mediated immunity. II. Effect on delayed-type hypersensitivity in the mouse and guinea pig, and cell-mediated immunity to tumour antigens in the mouse of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacteriumparvum, Bordetella pertussis, muramyl dipeptide and saponin. Clin Exp Immunol 39 (2): 435-441.
22. Shi Y, Evans JE, Rock KL (2003). Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425 (6957): 516-621.
23. Shi Y, Mucsi AD, Ng G (2010). Monosodium urate crystals in inflammation and immunity. Immunol Rev 233 (1): 203-217.
24. Kang SJ, Locksley RM (2009). The inflammasome and alummediated adjuvanticity. Biol Rep 1.p: 15.
25. Pétrilli V, Dostert C, Muruve DA, Tschopp J (2007). The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 19 (6): 615-622.
26. Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, Clemens R (2010). Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 126 (4): 762-770.
27. Heijmans S, De Meulemeester M, Reynders P, Giet D, Demanet E, Devresse PY, Icardi G, Dramé M, Roman F, Gillard P (2011). Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis 203 (8): 1054-1062.
28. Tritto E, Mosca F, De Gregorio E (2009). Mechanism of action of licensed vaccine adjuvants. Vaccine 27 (25-26): 3331-3334.
29. Monie A, Hung CF, Roden R, Wu TC (2008). Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics 2 (1): 97-105.
30. Brewer JM, Alexander J (1997). Cytokines and the mechanisms of action of vaccine adjuvants. Cytokines Cell Mol Ther 3 (4):233-246.
31. Hammad H, Lambrecht BN (2008). Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. Nat Rev Immunol 8 (3): 193-204.
32. Steinman RM, Pope M (2002). Exploiting dendritic cells to improve vaccine efficiency. J ClinInvest 109 (12): 1519-1526.
33. Bendelac A, Medzhitov R (2002). Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J Exp Med 195 (5): F19-23.
34. van Rijt LS, Lambrecht BN (2005). Dendritic cells in asthma: a function beyond sensitization. Clin Exp Allergy 2005 35 (9): 1125-1134.
35. Sokolovska A, Hem SL, HogenEsch H (2007). Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants. Vaccine 25 (23): 4575-4585.
36. Sallusto F, Cella M, Danieli C, Lanzavecchia A (1995). Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 182 (2): 389-400.
37. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K (2000). Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811.
38. Lanzavecchia A (1996). Mechanisms of antigen uptake for presentation. Curr Opin Immunol 3: 348-354.
39. Idzko M, Hammad H, van Nimwegen M, Kool M, Willart MA, Muskens F, Hoogsteden HC, Luttmann W, Ferrari D, Di Virgilio F, Virchow JC Jr, Lambrecht BN (2007). Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med 13 (8): 913-919.
40. Mempel TR, Henrickson SE, Von Andrian UH (2004). T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427 (6970): 154-159.
41. Cunningham AJ, Lafferty KJ (1977). A simple conservative explanation of the H-2 restriction of interactions between lymphocytes. Scand J Immunol 6 (1-2): 1-6.
42. Lenschow DJ, Walunas TL, Bluestone JA (1996). CD28/B7 system of T cell costimulation. Annu Rev Immunol 14: 233-258.
43. Mueller DL, Jenkins MK, Schwartz RH (1989). Clonal expansion versus functional clonal inactivation: a costimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 7: 445-480.
44. Kaliński P, Hilkens CM, Wierenga EA, Kapsenberg ML (1999). Tcell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 20 (12): 561-567.
45. Sornasse T, Flamand V, De Becker G, Bazin H, Tielemans F, Thielemans K, Urbain J, Leo O, Moser M (1992). Antigen pulsed dendritic cells can efficiently induce an antibody response et al. Antigen pulsed dendritic cells can efficiently induce an antibody response in vivo. J Exp Med 175: 15-21.
46. Cruz CM, Rinna A, Forman HJ, Ventura AL, Persechini PM, Ojcius DM (2007). ATP activates a oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages. J Biol Chem 282 (5): 2871-2879.
47. Lotze MT, Tracey KJ (2005). High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5 (4): 331-342.
48. Brewer JM, Conacher M, Hunter CA, Mohrs M, Brombacher F, Alexander J (1999). Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol 163 (12): 6448-6454.
49. Brewer JM, Conacher M, Gaffney M, Douglas M, Bluethmann H, Alexander J (1998). Neither interleukin-6 nor signalling via tumour necrosis factor receptor-1 contribute to the adjuvant activity of Alum and Freund's adjuvant. Immunology 93 (1): 41-48.
50. Brewer JM, Conacher M, Satoskar A, Bluethmann H, Alexander J (1996). In interleukin-4 deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 26: 2062-2066.
51. Gupta RK, Chang AC, Griffin P, Rivera R, Siber GR (1996). In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. Vaccine 14 (15): 1412-1416.
52. Lindblad EB (2004). Aluminium adjuvants--in retrospect and prospect. Vaccine 22 (27-28): 3658-3668.
53. HogenEsch H (2002). Mechanism of stimulation of the immune response of aluminium adjuvants. Vaccine 20 (3): S34-39.
54. Kool M, Soullié T, van Nimwegen M, Willart MA, Muskens F, Jung S, Hoogsteden HC, Hammad H, Lambrecht BN (2008). Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205 (4): 869-882.
55. Seubert A, Monaci E, Pizza M, O'Hagan DT, Wack A (2008). The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 180 (8): 5402-5412.
56. McKee AS, Munks MW, MacLeod MK, Fleenor CJ, Van Rooijen N, Kappler JW, et al (2009). Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 183 (7): 4403-4414.
57. Soehnlein O, Zernecke A, Eriksson EE, Rothfuchs AG, Pham CT, Herwald H, Bidzhekov K, Rottenberg ME, Weber C, Lindbom L (2008). Neutrophil secretion products pave the way for inflammatory monocytes. Blood 112 (4): 1461-1471.
58. Yang CW, Strong BS, Miller MJ, Unanue ER (2010). Neutrophils influence the level of antigen presentation during the immune response to protein antigens in adjuvants. J Immunol 185 (5): 2927-2934.
59. White RG, Coons AH, Connolly JM (1955). Studies on antibody production. III. The alum granuloma. J Exp Med 102: 73-82.
60. Vogelbruch M, Nuss B, Körner M, Kapp A, Kiehl P, Bohm W (2000). Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations. Allergy 55(9): 883-887.
61. McKee AS, MacLeod M, White J, Crawford F, Kappler JW, Marrack P (2008). Gr1+IL-4-producing innate cells are induced in response to Th2 stimuli and suppress Th1-dependent antibody responses. Int Immunol 20 (5): 659-669.
62. Ramanathan VD, Badenoch-Jones P, Turk JL (1979). Complement activation by aluminum and zirconium compounds. Immunology 37: 881-888.
63. Applequist SE, Dahlström J, Jiang N, Molina H, Heyman B (2000). Antibody production in mice deficient for complement receptors 1 and 2 can be induced by IgG/Ag and IgE/Ag, but not IgM/Ag complexes. J Immunol 165 (5): 2398-2403.
64. Wu X, Jiang N, Fang YF, Xu C, Mao D, Singh J, Fu YX, Molina H (2000). Impaired affinity maturation in Cr2-/- mice is rescued by adjuvants without improvement in germinal center development. J Immunol 165 (6): 3119-3127.
65. Rimaniol AC, Gras G, Verdier F, Capel F, Grigoriev VB, Porcheray F, Sauzeat E, Fournier JG, Clayette P, Siegrist CA, Dormont D (2004). Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 22(23-24): 3127-3135.
66. Ulanova M, Tarkowski A, Hahn-Zoric M, Hanson LA (2001). The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 69 (2): 1151-1159.
67. Sun H, Pollock KG, Brewer JM (2003). Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 21(9-10): 849-855.
68. Lindblad EB (2006). Are mineral adjuvants triggering TLR2/TLR4 on dendritic cells by a secondary cascade reaction in vivo through the action of heat shock proteins and danger signals? Vaccine 24 (6): 697-698.
69. Morefield GL, Sokolovska A, Jiang D, HogenEsch H, Robinson JP, Hem SL (2005). Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23(13): 1588-1595.
70. Mannhalter JW, Neychev HO, Zlabinger GJ, Ahmad R, Eibl MM (1985). Modulation of the human immune response by the nontoxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clin Exp Immunol 61(1): 143-151.
71. Glenny AT, Pope CG, Waddington H, Wallace U (1926). Immunological notes XVII to XXIV. J Pathol 29: 31-40.
72. Hansen B, Sokolovska A, HogenEsch H, Hem SL (2007). Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine 25 (36): 6618-6624.
73. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA (2008). Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453 (7198): 1122-1126.
74. Hem SL, Hogenesch H (2007). Relationship between physical and chemical properties of aluminium containing adjuvants and immunopotentiation. Vaccine 20 (3): 685-698.
75. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R (2001). Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2(10): 947-950.
76. Bortolatto J, Borducchi E, Rodriguez D, Keller AC, Faquim-Mauro E, Bortoluci KR, Mucida D, Gomes E, Christ A, Schnyder-Candrian S, Schnyder B, Ryffel B, Russo M (2008). Toll-like receptor 4 agonists adsorbed to aluminium hydroxide adjuvant attenuate ovalbumin-specific allergic airway disease: role of MyD88 adaptor molecule and interleukin-12/interferon-gamma axis. Clin Exp Allergy 38(10): 1668-1679.
77. Martinon F, Tschopp J (2005). NLRs join TLRs as innate sensors of pathogens. Trends Immunol 26 (8): 447-454.
78. Shaw MH, Reimer T, Kim YG, Nunez G (2008). NOD-like receptors (NLRs): bona fide intracellular microbial sensors. Curr Opin Immunol 20 (4): 377-382.
79. Mariathasan S, Monack DM (2007). Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 7 (1): 31-40.
80. Sutterwala FS, Ogura Y, Flavell RA (2007). The inflammasome in pathogen recognition and inflammation. J Leukoc Biol 82 (2): 259-264.
81. Matzinger P (2002). The danger model: a renewed sense of self. Science 296 (5566): 301-305.
82. Sutterwala FS, Ogura Y, Szczepanik M, Lara-Tejero M, Lichtenberger GS, Grant EP, Bertin J, Coyle AJ, Galán JE, Askenase PW, Flavell RA (2006). Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24 (3): 317-327.
83. Martinon F, Tschopp J (2004). Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117 (5): 561-574.
84. Fernandes-Alnemri T, Wu J, Yu JW, Datta P, Miller B, Jankowski W, Rosenberg S, Zhang J, Alnemri ES (2007). The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ 14 (9): 1590-1604.
85. Tschopp J, Martinon F, Burns K (2003). NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol 4 (2): 95-104.
86. Li H, Willingham SB, Ting JP, Re F (2008). Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 181 (1): 17-21.
87. Burns K, Martinon F, Tschopp J (2003). New insights into the mechanism of IL-1beta maturation. Curr Opin Immunol 15 (1): 26-30.
88. Kaye J, Gillis S, Mizel SB, Shevach EM, Malek TR, Dinarello CA, Lachman LB, Janeway CA Jr (1984). Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2. J Immunol 133 (3): 1339-1345.
89. Dunne A, O'Neill LA (2003). The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE (171): 53.
90. Meng G, Zhang F, Fuss I, Kitani A, Strober W (2009). A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 30 (6): 860-874.
91. Huber M, Beuscher HU, Rohwer P, Kurrle R, Röllinghoff M, Lohoff M (1998). Costimulation via TCR and IL-1 receptor reveals a novel IL-1alpha-mediated autocrine pathway of Th2 cell proliferation. J Immunol 160 (9): 4242-4247.
92. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, Dixit VM (2006). Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440 (7081): 228-232.
93. Pétrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J (2007). Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 14 (9): 1583-1589.
94. Franchi L, Kanneganti TD, Dubyak GR, Núñez G (2007). Differential requirement of P2X7 receptor and intracellular K+ for caspase-1 activation induced by intracellular and extracellular bacteria. J Biol Chem 282 (26): 18810-18818.
95. Walev I, Klein J, Husmann M, Valeva A, Strauch S, Wirtz H, Weichel O, Bhakdi S (2000). Potassium regulates IL-1 beta processing via calcium-independent phospholipase A2. J Immunol 164 (10): 5120-5124.
96. Andrei C, Margiocco P, Poggi A, Lotti LV, Torrisi MR, Rubartelli A (2004). Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes. Proc Natl Acad Sci USA 101 (26): 9745-9750.
97. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J (2010). Thioredoxin- interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11(2): 136-140.
98. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E (2008). Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9 (8): 847-856.
99. Sharp FA, Ruane D, Claass B, Creagh E, Harris J, Malyala P, Singh M, O'Hagan DT, Pétrilli V, Tschopp J, O'Neill LA, Lavelle EC (2009). Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci USA 106 (3): 870-875.
100. Hentze H, Lin XY, Choi MS, Porter AG (2003). Critical role for cathepsin B in mediating caspase-1-dependent interleukin-18 maturation and caspase-1-independent necrosis triggered by the microbial toxin nigericin. Cell Death Differ 10 (9): 956-968.
101. Li H, Nookala S, Re F (2007). Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 178 (8): 5271-5276.
102. Kool M, Petrilli V, De Smedt T, Rolaz A, Hammad H, van Nimwegen M, et al. (2008). Cutting Edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 181 (6): 3755-3759.
103. Franchi L, Nunez G (2008). The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 38 (8): 2085-2089.
104. Puren AJ, Fantuzzi G, Gu Y, Su MS, Dinarello CA (1998). Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest 101 (3): 711-721.
105. Flach TL, Ng G, Hari A, Desrosiers MD, Zhang P, Ward SM, Seamone ME, Vilaysane A, Mucsi AD, Fong Y, Prenner E, Ling CC, Tschopp J, Muruve DA, Amrein MW, Shi Y (2011). Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 17 (4): 479-487.
106. Greenberg S, Chang P, Wang DC, Xavier R, Seed B (1996). Clustered syk tyrosine kinase domains trigger phagocytosis. Proc Natl Acad Sci USA 93(3): 1103-1107.
107. Nakashima K, Kokubo T, Shichijo M, Li YF, Yura T, Yamamoto N (2004). A novel Syk kinase-selective inhibitor blocks antigen presentation of immune complexes in dendritic cells. Eur J Pharmacol 505 (1-3): 223-228.
108. Turner M, Schweighoffer E, Colucci F, Di Santo JP, Tybulewicz VL (2000). Tyrosine kinase SYK: essential functions for immunoreceptorsignalling. Immunol Today 21(3): 148-154.
109. Siraganian RP, Zhang J, Suzuki K, Sada K (2002). Protein tyrosine kinase Syk in mast cell signaling. Mol Immunol 38 (16-18): 1229-1233.
110. Ng G, Sharma K, Ward SM, Desrosiers MD, Stephens LA, Schoel WM, Li T, Lowell CA, Ling CC, Amrein MW, Shi Y (2008). Receptor-independent, direct membrane binding leads to cellsurface lipid sorting and Syk kinase activation in dendritic cells. Immunity 29 (5): 807-818.
111. Popa-Nita O, Proulx S, Paré G, Rollet-Labelle E, Naccache PH (2009). Crystal-induced neutrophil activation: XI. Implication and novel roles of classical protein kinase C. J Immunol 183 (3): 2104-2114
112. Kuroda E, Ishii KJ, Uematsu S, Ohata K, Coban C, Akira S, Aritake K, Urade Y, Morimoto Y (2011). Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity 34 (4): 514-526.
113. Goto N, Kato H, Maeyama J, Eto K, Yoshihara S (1993). Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines. Vaccine 11 (9): 914-918.
114. Goto N, Akama K (1984). Local histopathological reactions to aluminum-adsorbed tetanus toxoid. Naturwissenschaften 71 (8): 427-428.
115. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440 (7081): 237-241.
116. Kool M, Willart MA, van Nimwegen M, Bergen I, Pouliot P, Virchow JC, Rogers N, Osorio F, Reis E, Sousa C, Hammad H, Lambrecht BN (2011). An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity 34 (4): 527-540
117. Shi Y, Zheng W, Rock KL (2000). Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci USA 97(26): 14590-14595.
118. Kanevets U, Sharma K, Dresser K, Shi Y (2009). A role of IgM antibodies in monosodium urate crystal formation and associated adjuvanticity. J Immunol 182 (4): 1912-1918.
119. Marichal T, Ohata K, Bedoret D, Mesnil C, Sabatel C, Kobiyama K, Lekeux P, Coban C, Akira S, Ishii KJ, Bureau F, Desmet CJ (2011). DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 17 (8): 996-1002.